A Toronto man, Paul Lonergan, faced a health scare in 2023 when he discovered a tumor at the base of his tongue after months of persistent throat pain. Lonergan underwent a rigorous treatment regimen involving radiation and chemotherapy to eliminate the tumor. Despite successful treatment, a liquid biopsy revealed residual tumor DNA in his bloodstream, indicating a potential recurrence. Subsequent immunotherapy rendered Lonergan cancer-free.
Liquid biopsies, a novel cancer monitoring method, are not widely accessible in Canada but show promise in revolutionizing disease surveillance. Dr. Ramy Saleh of McGill University Health Centre sees potential in liquid biopsies for disease recurrence monitoring.
A Toronto research team at University Health Network (UHN) is embarking on a large-scale clinical trial, named SHERLOCK, to assess the utility of liquid biopsies in post-treatment cancer surveillance. Led by Dr. Lillian Siu, the study aims to identify early signs of cancer recurrence through circulating tumor DNA detection in the blood.
Liquid biopsies, a decade-old technology, offer a minimally invasive approach to cancer monitoring. Recent advancements have improved their sensitivity and accuracy, making them a valuable tool for early disease detection and improved patient outcomes.
Despite its potential, the use of liquid biopsies raises ethical dilemmas, as some patients may not wish to know about residual cancer cells. Ongoing research is essential to optimize the effectiveness of liquid biopsies and address concerns about false results.
The hope is to integrate liquid biopsies into routine patient care, although cost implications remain a challenge. Clinical trials like the one at UHN aim to demonstrate the cost-effectiveness and benefits of liquid biopsies in cancer care, potentially reshaping the future of cancer monitoring and treatment.
